Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455138 | 0.93 | — | — | |
| SCHEMBL18169999 | 0.93 | — | — | |
| SCHEMBL18169897 | 0.93 | — | — | |
| SCHEMBL5043492 | 0.89 | — | — | |
| SCHEMBL18169700 | 0.89 | — | — | |
| SCHEMBL18169960 | 0.89 | — | — | |
| SCHEMBL1039174 | 0.87 | NPC1 (0.32) | KDM4EALDH1A1 | |
| SCHEMBL9366837 | 0.83 | TAAR1 (0.35) | EPHX1NAAA | |
| SCHEMBL1039310 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1038975 | 0.79 | ALDH1A1 (0.34) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633733-B1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | UNIV TENNESSEE RES FOUNDATION (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20070167514-A1 | Cannabinoid derivatives, methods of making, and use thereof | UNIVERSTIY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-19 | — | — | US | disclosed |
| EP-1633733-A4 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | UNIV TENNESSEE RES CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7169942-B2 | agonists or antagonists; treatment for neuroinflammatory pathologies involving demyelinization, viral encephalitis, cerebrovascular accidents, cranial trauma, ocular disorders, pulmonary disorders, allergic diseases, inflammatory conditions, immune system disorders, central nervous system diseases, etc. | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1633733-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004113320-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040242593-A1 | Cannabinoid derivatives, methods of making, and use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242593-A1 | Cannabinoid derivatives, methods of making, and use thereof | CNR2, CNR1, GPR18 | EPHX1 1124/4885NAAA 443/4885KDM4E 2178/4885 |
| US-20070167514-A1 | Cannabinoid derivatives, methods of making, and use thereof | CNR2, CNR1, GPR18 | EPHX1 1075/4885NAAA 466/4885KDM4E 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.